The Medivive NAD+ Pen is a prescription sterile preparation containing nicotinamide adenine dinucleotide (NAD+). It's produced under cGMP at a 503B outsourcing facility and dispensed from a nationwide 503A pharmacy. Each pen is a 30-day supply (1,000 mg total) designed for subcutaneous (under the skin) administration as prescribed by a licensed clinician.

The Medivive NAD+ pen was originally developed by SpectrumX in the United Kingdom through a full drug development program. SpectrumX holds a Medical Specials license, a rare UK regulatory designation where every other holder is an NHS hospital.

Medivive is SpectrumX's exclusive US commercialization partner. Through technology transfer led by Medivive, the formulation is now manufactured at VeV Scientific, an FDA-registered cGMP 503B outsourcing facility in San Diego, to the same standard as the original UK product.

Learn more on our Our Story page.

Yes. Each batch is produced and sterilized under aseptic conditions in a certified ISO-class cleanroom. Sterility testing and endotoxin testing are performed on every batch before release.

Absolutely. Certificates of Analysis and batch sterility reports are available upon request. These confirm product potency, sterility, and compliance with quality standards.

Keep your pen refrigerated between 2–8°C (36–46°F) at all times.

Do not freeze the pen.

If the pen is left unrefrigerated for a few hours, it remains stable at room temperature for short periods, but prolonged exposure should be avoided to maintain potency.

Each pen is labeled with a Beyond-Use Date (BUD) that reflects validated stability data. Typically, pens are stable for several months under proper refrigeration. Always check the label before use.

Use the pen subcutaneously (under the skin) in areas such as the abdomen or thigh.

  1. Wash hands and clean the injection site with alcohol.
  2. Remove the cap and prime if needed.
  3. Insert the needle into the skin at a 45–90° angle.
  4. Depress the plunger slowly until the full dose is delivered.
  5. Keep the needle inserted for 10–15 seconds before removing.
  6. Dispose of the pen properly in a sharps container.

For complete illustrated instructions, download the official guide.

Some minor dripping at the injection site is completely normal. To minimize this, keep the needle in place for 10–15 seconds after depressing the plunger. Even with this precaution, a small amount of fluid loss can occur and is not cause for concern.

The yellow color is completely normal and indicates our high-concentration 1000mg formula. NAD+ molecules absorb most wavelengths of visible light except yellow, which is transmitted, giving the solution its characteristic color.

We do not use additives like mannitol to remove this natural coloration, as it has no impact on the safety, efficacy, or quality of the product. A more concentrated NAD+ solution will appear more intensely yellow.

While a yellow color is normal, cloudiness or visible particles are not. If you notice cloudiness, floating particles, or anything unusual beyond the expected yellow color, do not use the pen. Contact your provider or pharmacy for replacement guidance.

Yes. Use a cold-pack travel case to maintain the pen between 36–46°F (2–8°C) during transport. Avoid direct sunlight or freezing.

When flying, keep it in your carry-on bag, not checked luggage.

NAD+ is not an FDA-approved drug. The Medivive NAD+ Pen is a compounded preparation originally developed by SpectrumX in the UK through a full drug development program. It is manufactured at an FDA-registered 503B outsourcing facility under cGMP standards, and dispensed by a licensed, PCAB-accredited 503A pharmacy pursuant to valid, patient-specific prescriptions from licensed physicians.

Subcutaneous delivery bypasses the digestive system, providing higher bioavailability and faster systemic absorption than oral NAD+ precursors such as NR or NMN. This means more NAD+ reaches the bloodstream and target tissues.

Only licensed medical professionals with appropriate credentials (e.g., MD, DO, NP, PA) can prescribe this product. It is dispensed by licensed mail-order pharmacies and intended for patient use under supervision.

Medivive is a Trusted Partner of the SSRP Institute, the leading clinical education organization for cellular medicine and peptide therapeutics founded by Dr. William Seeds, MD.

The SSRP Trusted Partner program is invitation-only and compensation-free. The Institute promotes only brands that its faculty trusts and uses in their own clinical protocols.

Learn more on our Partners page.

Dr. William Seeds discussed the science behind NAD+ therapy and the Medivive pen on the Redox Revolution podcast.

Our Partners page includes the episode. You can also review the references at the bottom of this page.

No. Each pen is designed for single-patient, multi-use with disposable sterile needles. Use a new sterile needle for each injection. Never share your pen with others.

Needles and alcohol swabs are included with your kit. If you need additional needles, search for 31G 5mm needle tips on Amazon or at your local pharmacy.

Simply resume your regular dosing schedule. Do not double up or take extra doses to compensate.

Used pens and needles must be placed in a FDA-cleared sharps disposal container. When full, follow your local pharmacy or health department's disposal instructions.

Consult your prescribing clinician. Many longevity and metabolic programs combine NAD+ therapy with other regenerative or peptide therapies, but all combinations should be reviewed for safety and compatibility.

No FAQs found matching your search. Try different keywords.

Key Clinical References

  1. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22:119-141.
  2. Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLOS ONE. 2012;7(7):e42357.
  3. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213.
  4. Grant R, Berg J, Mestayer R, et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Front Aging Neurosci. 2019;11:257.
  5. Fang EF, et al. NAD+ in Aging: Molecular Mechanisms and Translational Implications. Trends Mol Med. 2017;23(10):899-916.
  6. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471.
  7. Gomes AP, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624-1638.